Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 7 of 7 entries
Sorted by: Best Match Show Resources per page
Circulating aberrant plasma cells allows risk stratification of patients with myeloma.

American journal of hematology

Periago A, Campillo JA, Mrowiec A, Gimeno L, Montes NR, Martínez-Sánchez MV, Cabañas-Perianes V, García-Garay C, Bolarin JM, Blasco-Mogorrón A, Muro M, Berenguer M, Moraleda JM, García-Alonso AM, Minguela A.
PMID: 27220360
Am J Hematol. 2016 Sep;91(9):E353-E355. doi: 10.1002/ajh.24431. Epub 2016 May 24.

No abstract available.

Cite
Periago A, Campillo JA, Mrowiec A, et al. Circulating aberrant plasma cells allows risk stratification of patients with myeloma. Am J Hematol. 2016;91(9):E353-E355doi: 10.1002/ajh.24431.
Periago, A., Campillo, J. A., Mrowiec, A., Gimeno, L., Montes, N. R., Martínez-Sánchez, M. V., Cabañas-Perianes, V., García-Garay, C., Bolarin, J. M., Blasco-Mogorrón, A., Muro, M., Berenguer, M., Moraleda, J. M., García-Alonso, A. M., & Minguela, A. (2016). Circulating aberrant plasma cells allows risk stratification of patients with myeloma. American journal of hematology, 91(9), E353-E355. https://doi.org/10.1002/ajh.24431
Periago, Adela, et al. "Circulating aberrant plasma cells allows risk stratification of patients with myeloma." American journal of hematology vol. 91,9 (2016): E353-E355. doi: https://doi.org/10.1002/ajh.24431
Periago A, Campillo JA, Mrowiec A, Gimeno L, Montes NR, Martínez-Sánchez MV, Cabañas-Perianes V, García-Garay C, Bolarin JM, Blasco-Mogorrón A, Muro M, Berenguer M, Moraleda JM, García-Alonso AM, Minguela A. Circulating aberrant plasma cells allows risk stratification of patients with myeloma. Am J Hematol. 2016 Sep;91(9):E353-E355. doi: 10.1002/ajh.24431. Epub 2016 May 24. PMID: 27220360.
Copy Download .nbib Format: NLM
Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing.

Oncoimmunology

Martínez-Sánchez MV, Periago A, Legaz I, Gimeno L, Mrowiec A, Montes-Barqueros NR, Campillo JA, Bolarin JM, Bernardo MV, López-Álvarez MR, González C, García-Garay MC, Muro M, Cabañas-Perianes V, Fuster JL, García-Alonso AM, Moraleda JM, Álvarez-Lopez MR, Minguela A.
PMID: 27141379
Oncoimmunology. 2015 Oct 29;5(4):e1093721. doi: 10.1080/2162402X.2015.1093721. eCollection 2016 Apr.

Missing self recognition makes cancer sensitive to natural killer cell (NKc) reactivity. However, this model disregards the NKc licensing effect, which highly increases NKc reactivity through interactions of inhibitory killer cell immunoglobulin-like receptors (iKIR) with their cognate HLA-I ligands....

Cite
Martínez-Sánchez MV, Periago A, Legaz I, et al. Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing. Oncoimmunology. 2015;5(4):e1093721doi: 10.1080/2162402X.2015.1093721.
Martínez-Sánchez, M. V., Periago, A., Legaz, I., Gimeno, L., Mrowiec, A., Montes-Barqueros, N. R., Campillo, J. A., Bolarin, J. M., Bernardo, M. V., López-Álvarez, M. R., González, C., García-Garay, M. C., Muro, M., Cabañas-Perianes, V., Fuster, J. L., García-Alonso, A. M., Moraleda, J. M., Álvarez-Lopez, M. R., & Minguela, A. (2016). Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing. Oncoimmunology, 5(4), e1093721. https://doi.org/10.1080/2162402X.2015.1093721
Martínez-Sánchez, María V, et al. "Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing." Oncoimmunology vol. 5,4 (2016): e1093721. doi: https://doi.org/10.1080/2162402X.2015.1093721
Martínez-Sánchez MV, Periago A, Legaz I, Gimeno L, Mrowiec A, Montes-Barqueros NR, Campillo JA, Bolarin JM, Bernardo MV, López-Álvarez MR, González C, García-Garay MC, Muro M, Cabañas-Perianes V, Fuster JL, García-Alonso AM, Moraleda JM, Álvarez-Lopez MR, Minguela A. Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing. Oncoimmunology. 2015 Oct 29;5(4):e1093721. doi: 10.1080/2162402X.2015.1093721. eCollection 2016 Apr. PMID: 27141379; PMCID: PMC4839374.
Copy Download .nbib Format: NLM
Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment.

American journal of cancer research

Minguela A, Vasco-Mogorrón MA, Campillo JA, Cabañas V, Remigia MJ, Berenguer M, García-Garay MC, Blanquer M, Cava C, Galian JA, Gimeno L, Soto-Ramírez MF, Martínez-Hernández MD, de la Rubia J, Teruel AI, Muro M, Periago A.
PMID: 34659897
Am J Cancer Res. 2021 Sep 15;11(9):4438-4454. eCollection 2021.

Improved therapies in multiple myeloma (MM) have forced a constant risk stratification update, first Durie-Salmon, then international scoring systems (ISS), next revised-ISS (RISS) including high-risk cytogenetic abnormalities (HRCAs) such as del(17p) and t(4;14), and now R2-ISS including 1q21 gain...

Cite
Minguela A, Vasco-Mogorrón MA, Campillo JA, et al. Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment. Am J Cancer Res. 2021;11(9):4438-4454
Minguela, A., Vasco-Mogorrón, M. A., Campillo, J. A., Cabañas, V., Remigia, M. J., Berenguer, M., García-Garay, M. C., Blanquer, M., Cava, C., Galian, J. A., Gimeno, L., Soto-Ramírez, M. F., Martínez-Hernández, M. D., de la Rubia, J., Teruel, A. I., Muro, M., & Periago, A. (2021). Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment. American journal of cancer research, 11(9), 4438-4454.
Minguela, Alfredo, et al. "Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment." American journal of cancer research vol. 11,9 (2021): 4438-4454.
Minguela A, Vasco-Mogorrón MA, Campillo JA, Cabañas V, Remigia MJ, Berenguer M, García-Garay MC, Blanquer M, Cava C, Galian JA, Gimeno L, Soto-Ramírez MF, Martínez-Hernández MD, de la Rubia J, Teruel AI, Muro M, Periago A. Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment. Am J Cancer Res. 2021 Sep 15;11(9):4438-4454. eCollection 2021. PMID: 34659897; PMCID: PMC8493371.
Copy Download .nbib Format: NLM
Blood-based risk stratification for pre-malignant and symptomatic plasma cell neoplasms to improve patient management.

American journal of cancer research

Vasco-Mogorrón MA, Campillo JA, Periago A, Cabañas V, Berenguer M, García-Garay MC, Gimeno L, Soto-Ramírez MF, Martínez-Hernández MD, Muro M, Minguela A.
PMID: 34249425
Am J Cancer Res. 2021 Jun 15;11(6):2736-2753. eCollection 2021.

Standard risk stratification (sRisk) guides clinical management in monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM) and multiple myeloma (MM). Nonetheless, clinical results are considerably heterogeneous among patients with similar risk status. Blood and bone marrow samples...

Cite
Vasco-Mogorrón MA, Campillo JA, Periago A, et al. Blood-based risk stratification for pre-malignant and symptomatic plasma cell neoplasms to improve patient management. Am J Cancer Res. 2021;11(6):2736-2753
Vasco-Mogorrón, M. A., Campillo, J. A., Periago, A., Cabañas, V., Berenguer, M., García-Garay, M. C., Gimeno, L., Soto-Ramírez, M. F., Martínez-Hernández, M. D., Muro, M., & Minguela, A. (2021). Blood-based risk stratification for pre-malignant and symptomatic plasma cell neoplasms to improve patient management. American journal of cancer research, 11(6), 2736-2753.
Vasco-Mogorrón, María A, et al. "Blood-based risk stratification for pre-malignant and symptomatic plasma cell neoplasms to improve patient management." American journal of cancer research vol. 11,6 (2021): 2736-2753.
Vasco-Mogorrón MA, Campillo JA, Periago A, Cabañas V, Berenguer M, García-Garay MC, Gimeno L, Soto-Ramírez MF, Martínez-Hernández MD, Muro M, Minguela A. Blood-based risk stratification for pre-malignant and symptomatic plasma cell neoplasms to improve patient management. Am J Cancer Res. 2021 Jun 15;11(6):2736-2753. eCollection 2021. PMID: 34249425; PMCID: PMC8263680.
Copy Download .nbib Format: NLM
Low-affinity immunoglobulin gamma Fc region receptor III-B (FcγRIIIB, CD16B) deficiency in patients with blood and immune system disorders.

British journal of haematology

Minguela A, Salido EJ, Soto-Ramírez MF, Olga MA, Leal JD, García-Garay MC, Periago A, Berenguer M, Blanque M, Campillo JA.
PMID: 34544201
Br J Haematol. 2021 Dec;195(5):743-747. doi: 10.1111/bjh.17828. Epub 2021 Sep 20.

Low-affinity immunoglobulin gamma Fc region receptor III-B (FcγRIIIB) deficiency is present in ˜0·05% of the general population. Among our patients, FcγRIIIB deficiency was less frequent in those with immune-system disorders (one of 1815 patients, 0·05%) than in those with...

Cite
Minguela A, Salido EJ, Soto-Ramírez MF, et al. Low-affinity immunoglobulin gamma Fc region receptor III-B (FcγRIIIB, CD16B) deficiency in patients with blood and immune system disorders. Br J Haematol. 2021;195(5):743-747doi: 10.1111/bjh.17828.
Minguela, A., Salido, E. J., Soto-Ramírez, M. F., Olga, M. A., Leal, J. D., García-Garay, M. C., Periago, A., Berenguer, M., Blanque, M., & Campillo, J. A. (2021). Low-affinity immunoglobulin gamma Fc region receptor III-B (FcγRIIIB, CD16B) deficiency in patients with blood and immune system disorders. British journal of haematology, 195(5), 743-747. https://doi.org/10.1111/bjh.17828
Minguela, Alfredo, et al. "Low-affinity immunoglobulin gamma Fc region receptor III-B (FcγRIIIB, CD16B) deficiency in patients with blood and immune system disorders." British journal of haematology vol. 195,5 (2021): 743-747. doi: https://doi.org/10.1111/bjh.17828
Minguela A, Salido EJ, Soto-Ramírez MF, Olga MA, Leal JD, García-Garay MC, Periago A, Berenguer M, Blanque M, Campillo JA. Low-affinity immunoglobulin gamma Fc region receptor III-B (FcγRIIIB, CD16B) deficiency in patients with blood and immune system disorders. Br J Haematol. 2021 Dec;195(5):743-747. doi: 10.1111/bjh.17828. Epub 2021 Sep 20. PMID: 34544201.
Copy Download .nbib Format: NLM
Low-affinity immunoglobulin gamma Fc region receptor III-B (FcγRIIIB, CD16B) deficiency in patients with blood and immune system disorders.

British journal of haematology

Minguela A, Salido EJ, Soto-Ramírez MF, Olga MA, Leal JD, García-Garay MC, Periago A, Berenguer M, Blanque M, Campillo JA.
PMID: 34544201
Br J Haematol. 2021 Dec;195(5):743-747. doi: 10.1111/bjh.17828. Epub 2021 Sep 20.

Low-affinity immunoglobulin gamma Fc region receptor III-B (FcγRIIIB) deficiency is present in ˜0·05% of the general population. Among our patients, FcγRIIIB deficiency was less frequent in those with immune-system disorders (one of 1815 patients, 0·05%) than in those with...

Cite
Minguela A, Salido EJ, Soto-Ramírez MF, et al. Low-affinity immunoglobulin gamma Fc region receptor III-B (FcγRIIIB, CD16B) deficiency in patients with blood and immune system disorders. Br J Haematol. 2021;195(5):743-747doi: 10.1111/bjh.17828.
Minguela, A., Salido, E. J., Soto-Ramírez, M. F., Olga, M. A., Leal, J. D., García-Garay, M. C., Periago, A., Berenguer, M., Blanque, M., & Campillo, J. A. (2021). Low-affinity immunoglobulin gamma Fc region receptor III-B (FcγRIIIB, CD16B) deficiency in patients with blood and immune system disorders. British journal of haematology, 195(5), 743-747. https://doi.org/10.1111/bjh.17828
Minguela, Alfredo, et al. "Low-affinity immunoglobulin gamma Fc region receptor III-B (FcγRIIIB, CD16B) deficiency in patients with blood and immune system disorders." British journal of haematology vol. 195,5 (2021): 743-747. doi: https://doi.org/10.1111/bjh.17828
Minguela A, Salido EJ, Soto-Ramírez MF, Olga MA, Leal JD, García-Garay MC, Periago A, Berenguer M, Blanque M, Campillo JA. Low-affinity immunoglobulin gamma Fc region receptor III-B (FcγRIIIB, CD16B) deficiency in patients with blood and immune system disorders. Br J Haematol. 2021 Dec;195(5):743-747. doi: 10.1111/bjh.17828. Epub 2021 Sep 20. PMID: 34544201.
Copy Download .nbib Format: NLM
Correction: Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.

Oncotarget

Raneros AB, Minguela A, Rodriguez RM, Colado E, Bernal T, Anguita E, Mogorron AV, Gil AC, Vidal-Castiñeira JR, Márquez-Kisinousky L, Bulnes PD, Marin AM, García Garay MC, Suarez-Alvarez B, Lopez-Larrea C.
PMID: 30214691
Oncotarget. 2018 Aug 28;9(67):32881. doi: 10.18632/oncotarget.26079. eCollection 2018 Aug 28.

[This corrects the article DOI: 10.18632/oncotarget.16657.].

Cite
Raneros AB, Minguela A, Rodriguez RM, et al. Correction: Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition. Oncotarget. 2018;9(67):32881doi: 10.18632/oncotarget.26079.
Raneros, A. B., Minguela, A., Rodriguez, R. M., Colado, E., Bernal, T., Anguita, E., Mogorron, A. V., Gil, A. C., Vidal-Castiñeira, J. R., Márquez-Kisinousky, L., Bulnes, P. D., Marin, A. M., García Garay, M. C., Suarez-Alvarez, B., & Lopez-Larrea, C. (2018). Correction: Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition. Oncotarget, 9(67), 32881. https://doi.org/10.18632/oncotarget.26079
Raneros, Aroa Baragaño, et al. "Correction: Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition." Oncotarget vol. 9,67 (2018): 32881. doi: https://doi.org/10.18632/oncotarget.26079
Raneros AB, Minguela A, Rodriguez RM, Colado E, Bernal T, Anguita E, Mogorron AV, Gil AC, Vidal-Castiñeira JR, Márquez-Kisinousky L, Bulnes PD, Marin AM, García Garay MC, Suarez-Alvarez B, Lopez-Larrea C. Correction: Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition. Oncotarget. 2018 Aug 28;9(67):32881. doi: 10.18632/oncotarget.26079. eCollection 2018 Aug 28. PMID: 30214691; PMCID: PMC6132351.
Copy Download .nbib Format: NLM
Showing 1 to 7 of 7 entries